de Oliveira CC, Brizeno LAC, de Sousa FB, Mota MRL, Alves APNN. Osteonecrosis of the jaw induced by receptor activator of nuclear factor-kappa B ligand (Denosumab) - Review. Med Oral Patol Oral Cir Bucal. 2016 Jul 1;21 (4):e431-9.

 

 

doi:10.4317/medoral.21044

http://dx.doi.org/doi:10.4317/medoral.21044

 

 

1. Narayan P. Denosumab: A compressive review. South Asia J Cancer. 2013;2:272-7.
http://dx.doi.org/10.4103/2278-330X.119895

 

2. Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, Boer RH, et al. Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study. J Clin Oncol. 2010;28:5132-9.
http://dx.doi.org/10.1200/JCO.2010.29.7101

 

3. Henry DH, Costa L, Goldwasser F, Hirsch V, Hungria V, Prasouva J, et al. Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma. J Clin Oncol. 2011;29:1125-32.
http://dx.doi.org/10.1200/JCO.2010.31.3304

 

4. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw-2014 Update. J Oral Maxillofac Surg. 2014;72:1938-56.
http://dx.doi.org/10.1016/j.joms.2014.04.031

 

5. Yamashita J, McCauley LK. Antiresorptives and osteonecrosis of the jaw. J Evid Based Dent Pract. 2012;12(3 Suppl):233-47.
http://dx.doi.org/10.1016/S1532-3382(12)70046-5

 

6. Walter C, Al-Nawas B, Gro KA, Thomas C, Thuroff JW, Zinser V, et al. Prevalence and Risk Factors of Bisphosphonate-Associated Osteonecrosis of the Jaw in Prostate Cancer Patients with Advanced Disease Treated with Zoledronate. European Urology. 2008;54:1066-72.
http://dx.doi.org/10.1016/j.eururo.2008.06.070

 

7. Thumbigere-Math V, Tu L, Huckabay S, Dudek AZ, Lunos S, Basi DL, et al. A Retrospective Study Evaluating Frequency and Risk Factors of Osteonecrosis of the Jaw in 576 Cancer Patients Receiving Intravenous Bisphosphonates. Am J Clin Oncol. 2012;35:386-92.
http://dx.doi.org/10.1097/COC.0b013e3182155fcb

 

8. Otto S, Baumann S, Ehrenfeld M, Pautke C. Successful surgical management of osteonecrosis of the jaw due to RANK-ligand inhibitor treatment using fluorescence guided bone resection. Journal of Cranio-Maxillo-Facial Surgery. 2013;41:694-8.
http://dx.doi.org/10.1016/j.jcms.2013.05.038

 

9. O'Halloran M, Boyd NM, Smith A. Denosumab and osteonecrosis of the jaws – the pharmacology, pathogenesis and a report of two cases. Australian Dental Journal. 2014;59:516-9.
http://dx.doi.org/10.1111/adj.12217

 

10. Tortajada FC, Gmez ES, Lozano DV. Oral bisphosphonates, denosumab and osteonecrosis of the jaws. Aten Primaria. 2015;47:319-20.
http://dx.doi.org/10.1016/j.aprim.2014.07.005

 

11. Olate S, Uribe F, Martinez F, Almeida A, Unibazo A. Osteonecrosis of the jaw in patient with denosumab therapy. Int J Clin Exp Med. 2014;7:3707-9.

 

12. Rachner TD, Platzbecker U, Felsenberg D, Houfbauer LC. Osteonecrosis of Jaw After Osteoporosis Therapy With Denosumab Following Long-Term Bisphosphonate Therapy. Mayo Clin Proc. 2013;88:418-9.
http://dx.doi.org/10.1016/j.mayocp.2013.01.002

 

13. Neuprez A, Coste S, Rompen E, Crielaard M, Reginster JY. Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab. Osteoporos Int. 2014;25:393-5.
http://dx.doi.org/10.1007/s00198-013-2437-z

 

14. Aghaloo TL, Dry SM, Mallaya S, Tetradis S. Stage 0 Osteonecrosis of the Jaw in a Patient on Denosumab. J Oral Maxillofac Surg. 2013;72:702-16.
http://dx.doi.org/10.1016/j.joms.2013.09.008

 

15. Malan J, Ettinger K, Naumann E, Beirne R. The relationship of denosumab pharmacology and osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012;114:671-6.
http://dx.doi.org/10.1016/j.oooo.2012.08.439

 

16. Aghaloo TL, Felsenfeld AL, Tetradis S. Osteonecrosis of the Jaw in a Patient on Denosumab. J Oral Maxillofac Surg. 2010;68:959-63.
http://dx.doi.org/10.1016/j.joms.2009.10.010

 

17. Diz P, Lpez-Cedrn JL, Arenaz J, Scully C. Denosumab-related osteonecrosis of the jaw. J Am Dent Assoc. 2012;143:981-4.
http://dx.doi.org/10.14219/jada.archive.2012.0323

 

18. Pichardo SEC, Kuypers SCC, Van Merkesteyn JPR. Denosumab osteonecrosis of the mandible: A new entity?. A case report. Journal of Cranio-Maxillo-Facial Surgery. 2013;41:e65-e9.
http://dx.doi.org/10.1016/j.jcms.2012.10.014

 

19. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756-65.
http://dx.doi.org/10.1056/NEJMoa0809493

 

20. Selvi Sabater P, Rizo Cerd AM, Titos Arcos JC, Espuny Mir A. [Possible denosumab-induced jaw osteonecrosis in the treatment of osteoporosis. A case report]. Farm Hosp. 2014;38:248-9.

 

21. Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 2013;14:901-8.
http://dx.doi.org/10.1016/S1470-2045(13)70277-8

 

22. Hoff AO, Toth BM, Altundag K, Johnson MM, Warneke CL, Hu M, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Min Res. 2008;23:826-36.
http://dx.doi.org/10.1359/jbmr.080205

 

23. Scolleta M, Arduino PG, Dalmasso P, Brocolletti R, Mozzati M. Treatment outcomes in patients with bisphosphonate-related osteonecrosis of the jaws: a prospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;110:46-53.
http://dx.doi.org/10.1016/j.tripleo.2010.02.020

 

24. Alves C, Andion J, Brando M, Menezes R. [Pathogenic aspects of the periodontal disease associated to diabetes mellitus]. Arq Bras Endocrinol Metabol. 2007;51:1050-7.
http://dx.doi.org/10.1590/S0004-27302007000700005

 

25. Taylor KH, Middlefell LS, Mizen KD. Osteonecrosis of the jaws induced by anti-RANK ligand therapy. British Journal of Oral and Maxillofacial Surgery. 2010;48:221-3.
http://dx.doi.org/10.1016/j.bjoms.2009.08.030

 

26. Fantuzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005;115:911-9.
http://dx.doi.org/10.1016/j.jaci.2005.02.023

 

27. Izzotti A, Menini M, Pulliero A, Dini G, Cartiglia C, Pera P, et al. Biphosphonates-associated osteonecrosis of the jaw: the role of gene-environment interaction. J Prev Med Hyg. 2013;54:138-45.

 

28. Mc Leod NMH, Patel V, Kusanale A, Rogers SN, Brennan PA. Bisphosphonate osteonecrosis of the jaw: a literaturereview of UK policies versus international policies on the management of bisphosphonate osteonecrosis of the jaw. British Journal of Oral and Maxillofacial Surgery. 2011;49:335-42.
http://dx.doi.org/10.1016/j.bjoms.2010.08.005

 

29. Porcaro G, Amosso E, Scarpella R, Carini F. Doxycycline fluorescence-guided Er:YAG laser ablation combined with Nd:YAG/diode laser biostimulation for treating bisphosphonate-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;119:e6-e12.
http://dx.doi.org/10.1016/j.oooo.2014.04.014

 

30. Pelaz A, Junquera L, Gallego L, Garca-Consuegra L, Junquera S, Gmez C. Alternative treatments for oral bisphosphonate-related osteonecrosis of the jaws: A pilot study comparing fibrin rich in growth factors and teriparatide. Medicina Oral, Patologa Oral y Ciruga Bucal. 2014;19:e320-e6.
http://dx.doi.org/10.4317/medoral.19458